Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients
Authors
Djebbari, FaouziRampotas, Alexandros
Vallance, Grant
Panitsas, Fotios
Basker, Nanda
Sangha, Gina
Salhan, Beena
Karim, Farheen
Al-Kaisi, Firas
Gudger, Amy
Ngu, Loretta
Poynton, Matt
Lam, Ho Pui Jeff
Morgan, Lowri
Yang, Laura
Young, Jennifer
Walker, Mairi
Tsagkaraki, Ismini
Anderson, Laura
Chauhan, Saleena Rani
Maddams, Rebecca
Soutar, Richard
Triantafillou, Margarita
Prideaux, Steve
Obeidalla, Abubaker
Eyre, Toby A
Bygrave, Ceri
Kothari, Jaimal
Basu, Supratik

Ramasamy, Karthik
Issue Date
2023-01-31
Metadata
Show full item recordCitation
Djebbari, F., Rampotas, A., Vallance, G. et al. (2023) Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients. British Journal of Haematology. https://doi.org/10.1111/bjh.18672Publisher
WileyJournal
British Journal of HaematologyPubMed ID
36720464 (pubmed)Additional Links
https://onlinelibrary.wiley.com/doi/10.1111/bjh.18672Type
Journal articleLanguage
enDescription
This is an accepted manuscript of an article published by Wiley on 31/01/2023, available online: https://doi.org/10.1111/bjh.18672 The accepted version of the publication may differ from the final published version.ISSN
0007-1048EISSN
1365-2141ae974a485f413a2113503eed53cd6c53
10.1111/bjh.18672
Scopus Count
Collections
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/